Gonçalves Priscila Baltazar, Cordeiro Yraima, Rennó Sodero Ana Carolina
Faculdade de Farmácia, Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio de Janeiro RJ 21941-902 Brazil
RSC Adv. 2024 Jul 16;14(31):22525-22539. doi: 10.1039/d4ra03343d. eCollection 2024 Jul 12.
Oligomeric species of amyloid β peptide (Aβ) are pivotal in Alzheimer's disease (AD) pathogenesis, making them valuable therapeutic targets. Currently, there is no cure or preventive therapy available for AD, with only a few therapeutics offering temporary alleviation of symptoms. Natural products (NPs) are now considered promising anti-amyloid agents. Green tea catechins have garnered considerable attention due to their ability to remodel the toxic amyloid β peptide oligomers (AβOs) into non-toxic assemblies. Nevertheless, the precise molecular mechanism underlying their effects on AβOs remains unclear. In this study, we employ a combination of binding site prediction, molecular docking, and dynamics simulations to gain mechanistic insights into the binding of the potent anti-amyloid epigallocatechin-3-gallate (EGCG) and the less effective catechin, epicatechin (EC), on the structure of pore-forming Aβ tetramers (PDB ID 6RHY). This recently elucidated structure represents AβO with two faces of the hydrophobic β-sheet core and hydrophilic edges. Our simulations revealed three potential druggable binding sites within the AβO: two in hydrophilic edges and one in the β-sheet core. Although both catechins bind hydrogen bond (H-bond) and aromatic interactions to the three potential binding sites, EGCG interacted with key residues more efficiently than EC. We propose that EGCG may remodel AβOs preventing pore formation by binding to the hydrophilic edge binding sites. Additionally, EGCG interacts with key residues in the oligomer's β-sheet core binding site, crucial for fibrillar aggregation. A better understanding of how anti-amyloid compounds remodelling AβOs could be valuable for the development of new therapeutic strategies targeting Aβ in AD. Further experimental validation using point mutations involving key residues could be useful to define whether the establishment of these interactions is crucial for the EGCG remodelling effect.
淀粉样β肽(Aβ)的寡聚体在阿尔茨海默病(AD)发病机制中起关键作用,使其成为有价值的治疗靶点。目前,AD尚无治愈或预防性疗法,仅有少数疗法能暂时缓解症状。天然产物(NPs)现被认为是有前景的抗淀粉样蛋白药物。绿茶儿茶素因其能将有毒的淀粉样β肽寡聚体(AβOs)重塑为无毒聚集体的能力而备受关注。然而,其对AβOs作用的精确分子机制仍不清楚。在本研究中,我们结合结合位点预测、分子对接和动力学模拟,以深入了解强效抗淀粉样蛋白表没食子儿茶素-3-没食子酸酯(EGCG)和效果较差的儿茶素表儿茶素(EC)与成孔Aβ四聚体结构(PDB ID 6RHY)的结合机制。这种最近阐明的结构代表了具有疏水β-折叠核心和亲水边缘两面的AβO。我们的模拟揭示了AβO内三个潜在的可成药结合位点:两个位于亲水边缘,一个位于β-折叠核心。尽管两种儿茶素都通过氢键(H键)和芳香相互作用与这三个潜在结合位点结合,但EGCG比EC更有效地与关键残基相互作用。我们提出,EGCG可能通过与亲水边缘结合位点结合来重塑AβOs,从而防止孔形成。此外,EGCG与寡聚体β-折叠核心结合位点中的关键残基相互作用,这对纤维状聚集至关重要。更好地理解抗淀粉样蛋白化合物如何重塑AβOs对于开发针对AD中Aβ的新治疗策略可能很有价值。使用涉及关键残基的点突变进行进一步的实验验证,可能有助于确定这些相互作用的建立是否对EGCG的重塑效果至关重要。